Neovascular (Wet) Age-Related Macular DegenerationPhase 1/2OVERTURENCT07587515
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
A Phase 1/2 study testing EYC-0305 in people with Neovascular (Wet) Age-Related Macular Degeneration, run by Eyconis INC. at 7 sites in United States.
Trial summary
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Neovascular (Wet) Age-Related Macular Degeneration
- What is being tested?
- EYC-0305
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 7 sitesUnited States
- Study dates
- 19 May 2026to May 2028
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
Who cannot join
- Known hypersensitivity or known allergy that would preclude study drug administration
- Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
- Uncontrolled diabetes mellitus
- History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
- Renal failure, dialysis, or history of renal transplant
- Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
- Pregnant or breastfeeding women
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Bellaire, TX
Bellaire, Texas, 77401
- Recruiting
Beverly Hills, CA
Beverly Hills, California, 90211
- Recruiting
Erie, PA
Erie, Pennsylvania, 16505
- Recruiting
McAllen, TX
McAllen, Texas, 78503
- Recruiting
Modesto, CA
Modesto, California, 95356
- Recruiting
The Woodlands, TX
The Woodlands, Texas, 77384
- Recruiting
Wake Forest, NC
Wake Forest, North Carolina, 27587
About this study
Official title: Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
- Being tested
- EYC-0305
- Keywords
- EYC-0305, TransCon aVEGF, wet AMD, neovascular AMD, treatment naive, Eyconis, anti-VEGF
- Medical subject headings
- Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EYC-0305Biological
Extended-delivery anti-VEGF
| Study group | Role | What they receive |
|---|---|---|
| EYC-0305 Dose Level 1 | Experimental | Not described Receives: Biological: EYC-0305 |
| EYC-0305 Dose Level 2 | Experimental | Not described Receives: Biological: EYC-0305 |
| EYC-0305 Dose Level 3 | Experimental | Not described Receives: Biological: EYC-0305 |
| EYC-0305 Dose Level 4 | Experimental | Not described Receives: Biological: EYC-0305 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of ocular treatment-emergent adverse events (TEAEs)
Measured: Week 72
Incidence and severity of systemic treatment-emergent adverse events (TEAEs)
Measured: Week 72
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start19 May 2026
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular (Wet) Age-Related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eyconis INC.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07587515
- Sponsor's protocol ID
- EYC-0305-2501
- Acronym
- OVERTURE
- Status last verified
- Jun 2026
- First submitted
- 8 May 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD reported in results publication will be shared